P0771 Real-world outcomes of upadacitinib therapy for patient with inflammatory bowel disease in Korea: A multicentre study

Journal of Crohn s and Colitis 2026

View at publisher
Authors: B D Ye, M K Kim, E S Kim, S B Lee, S B Kang, K Seong-Joon, S W Hwang, S H Park, H Yoon, J S Byeon
DOI: 10.1093/ecco-jcc/jjaf231.952
Cited by: 1

Abstract

Abstract Background Upadacitinib (UPA) has demonstrated efficacy and safety for Crohn’s disease (CD) and ulcerative colitis (UC) in pivotal trials.1,2 However, real-world data in Asian patients remain limited. Methods We conducted a retrospective multicentre study including patients with CD or UC who initiated UPA across six referral hospitals in Korea between September 2023 and January 2025. Clinical remission/response, endoscopic outcomes (UC), biochemical outcomes, and safety were evaluated (week 12/24/52 in CD; week 16/52 in UC). Clinical remission was defined as CDAI

Fields of Study & Subjects

Inflammatory Bowel Disease Biosimilars and Bioanalytical Methods Microscopic Colitis

Publication details

Journal / source
Journal of Crohn s and Colitis
Publisher
Oxford University Press (OUP)
Volume
20
Issue
Supplement_1
Publication date
1 January 2026
Language
EN